Atogepant Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 10 mg, 30 mg, 60 mg
Reference Brands: Qulipta (USA)
Category:
Neurology
Atogepant is available in Tablets
and strengths such as 10 mg, 30 mg, 60 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Atogepant is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Atogepant can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Atogepant, marketed under the brand name Qulipta, is an orally administered medication approved for the preventive treatment of episodic migraine in adults. It belongs to the class of drugs known as gepants, which are calcitonin gene-related peptide (CGRP) receptor antagonists. By selectively blocking CGRP receptors, atogepant helps reduce the frequency, severity, and impact of migraine attacks, providing an effective prophylactic option for patients who experience recurrent migraines.
As a once-daily oral therapy, atogepant offers a convenient alternative to injectable migraine-preventive treatments. Clinical studies have shown that it significantly lowers the number of migraine days per month, improving overall quality of life for adults living with episodic migraine. The medication is generally well-tolerated, with the most common side effects including nausea and constipation. Atogepant represents a modern, targeted approach to migraine prevention, providing patients and healthcare providers with a valuable tool for long-term management of this debilitating neurological condition.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing